glp-1 employer healthcare costs As drug use surges nationwide, overall spending could soon drive up for everyone, according to a new study. MORE BELOW ⬇️ Employer FAQs on the Rise

Suicide and self-harm events with GLP-1 receptor agonists in adults with diabetes or obesity: a systematic review and meta-analysis

This creates an interesting divergence

Additionally, the evidence base for efficacy and safety specifically in BED populations remains limited

Tong, J

Sean Hashmi, MD, is the regional medical director of Lifestyle & Obesity Medicine for the Southern California Permanente Medical Group, and national chair of the interregional clinical practice group for Lifestyle & Obesity Medicine, The Permanente Federation.

However, it can amplify side effects like nausea, restlessness, and dehydration